Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.29B | 3.71B | 3.21B | 2.46B | 2.35B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.29B | 3.71B | 3.21B | 2.46B | 2.35B |
| Cost of Revenue | 821.95M | 681.87M | 516.97M | 402.72M | 328.44M |
| Gross Profit | 3.46B | 3.03B | 2.69B | 2.06B | 2.02B |
| SG&A Expenses | 1.29B | 1.21B | 1.18B | 1.08B | 1.00B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.53B | 3.21B | 2.95B | 2.64B | 2.46B |
| Operating Income | 752.14M | 501.58M | 264.70M | -180.19M | -115.37M |
| Income Before Tax | 586.40M | 362.38M | 7.29M | -340.35M | -316.16M |
| Income Tax Expenses | 9.18M | 9.41M | -75.51M | -60.49M | -85.68M |
| Earnings from Continuing Operations | 577.22 | 352.98 | 82.79 | -279.86 | -230.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 577.22M | 352.98M | 82.79M | -279.86M | -230.47M |
| EBIT | 752.14M | 501.58M | 264.70M | -180.19M | -115.37M |
| EBITDA | 806.94M | 557.24M | 321.02M | -123.69M | -57.82M |
| EPS Basic | 4.36 | 2.67 | 0.61 | -2.16 | -1.79 |
| Normalized Basic EPS | 2.78 | 1.73 | 0.21 | -1.63 | -1.51 |
| EPS Diluted | 4.21 | 2.56 | 0.54 | -2.17 | -1.79 |
| Normalized Diluted EPS | 2.66 | 1.66 | 0.16 | -1.63 | -1.51 |
| Average Basic Shares Outstanding | 527.20M | 523.98M | 520.87M | 518.01M | 514.12M |
| Average Diluted Shares Outstanding | 542.48M | 533.93M | 526.77M | 518.01M | 514.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |